; (ii) the cost of raw materials, the cost of energy, and related costs; (iii) taxes and other incentives; and (iv) the effects of regulations; and (B) the costs and consequences of implementing, or failing to implement, each such recommendation. (d) Input The agreement under subsection (a) shall require— (1) consideration of input from the Department of Health and Human Services, the Department of Commerce, and, as appropriate, other Federal agencies; and (2) consultation with relevant stakeholders, which— (A) may include conducting public meetings and other forms of engagement, as appropriate; (B) shall include consultation with experts in— (i) the manufacturing of drugs; (ii) pharmaceutical industry business and economics; (iii) drug purchasing, pricing, and reimbursement; (iv) regulatory and intellectual property issues affecting drug manufacturing; (v) economics; (vi) international trade policy; and (vii) emergency planning; and (C) may include consultation with other entities with experience in drug manufacturing and pricing, as appropriate. (e) Definitions In this section, the term drug has the meaning given such term in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ). D Essential Medicines Strategic Stockpile 2031. Pilot program on ensuring medication supply stability Part D of title III of the Public Health Service Act ( 42 U.S.C. 254b et seq.) is amended by adding at the end the following new subpart: XIII Ensuring Medication Supply Stability 340J. Ensuring medication supply stability (a) Award of contracts Beginning not later than January 1, 2021, the Secretary shall award contracts to eligible entities to each implement and test the effectiveness of acquiring, maintaining, managing, and distributing a stockpile that— (1) consists of generic drugs at risk of shortage